Therapy of hepatitis C: Re‐treatment with alpha interferon
A Alberti, L Chemello, F Noventa, L Cavalletto, GianLuca De Salvo – 30 December 2003 – The long‐term benefit of interferon therapy in chronic hepatitis C is limited. During therapy, serum alanine aminotransferase (ALT) levels decrease to normal and hepatitis C virus (HCV) RNA decreases in 40% to 60% of patients. However, most patients relapse after therapy withdrawal, so that no more than 15% to 25% achieve a sustained response.